Noah Berkowitz, the Chief Medical Officer of $ARVN, sold 8,658 shares of the company on 03-18-2025 for an estimated $74,372. We received data on the trade from a recent SEC filing. This was a sale of approximately 7.3% of their shares of this class of stock. Following this trade, they now own 110,023 shares of this class of $ARVN stock.
$ARVN Insider Trading Activity
$ARVN insiders have traded $ARVN stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $ARVN stock by insiders over the last 6 months:
- JOHN G HOUSTON (President and CEO) has made 0 purchases and 2 sales selling 31,338 shares for an estimated $523,880.
- IAN TAYLOR (President, R&D) has made 0 purchases and 2 sales selling 9,020 shares for an estimated $150,752.
- NOAH BERKOWITZ (Chief Medical Officer) sold 8,658 shares for an estimated $74,372
- ANGELA M CACACE (Chief Scientific Officer) has made 0 purchases and 2 sales selling 4,207 shares for an estimated $70,238.
- DAVID K LOOMIS (Chief Accounting Officer) has made 0 purchases and 2 sales selling 1,445 shares for an estimated $26,730.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ARVN Hedge Fund Activity
We have seen 102 institutional investors add shares of $ARVN stock to their portfolio, and 106 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP removed 2,339,961 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $44,857,052
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 2,208,234 shares (+inf%) to their portfolio in Q4 2024, for an estimated $42,331,845
- UBS GROUP AG added 1,566,881 shares (+332.3%) to their portfolio in Q4 2024, for an estimated $30,037,108
- FMR LLC removed 1,324,777 shares (-45.9%) from their portfolio in Q4 2024, for an estimated $25,395,975
- BRAIDWELL LP removed 1,284,472 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $24,623,328
- COMMODORE CAPITAL LP removed 1,200,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $23,004,000
- RTW INVESTMENTS, LP added 551,979 shares (+19.8%) to their portfolio in Q4 2024, for an estimated $10,581,437
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ARVN Analyst Ratings
Wall Street analysts have issued reports on $ARVN in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BMO Capital issued a "Outperform" rating on 03/12/2025
- Wells Fargo issued a "Overweight" rating on 03/12/2025
- BTIG issued a "Buy" rating on 12/10/2024
- Leerink Partners issued a "Outperform" rating on 11/19/2024
To track analyst ratings and price targets for $ARVN, check out Quiver Quantitative's $ARVN forecast page.
$ARVN Price Targets
Multiple analysts have issued price targets for $ARVN recently. We have seen 7 analysts offer price targets for $ARVN in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- An analyst from Morgan Stanley set a target price of $12.0 on 03/13/2025
- Etzer Darout from BMO Capital set a target price of $20.0 on 03/12/2025
- Derek Archila from Wells Fargo set a target price of $26.0 on 03/12/2025
- Jeet Mukherjee from BTIG set a target price of $69.0 on 12/10/2024
- Christopher Liu from Leerink Partners set a target price of $62.0 on 11/19/2024
- Matthew Biegler from Oppenheimer set a target price of $40.0 on 10/31/2024
- Bradley Canino from Stifel Nicolaus set a target price of $63.0 on 10/21/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
